BioSpace News Archive

The CALYPSO program will receive 14 million euros to develop CorWave Neptune, a new type of cardiac support to improve the management of patients with severe heart failure, as part of the Programme d’Investissements d’Avenir (PIA) operated by Bpifrance.

Adlai Nortye Biopharma Co., Ltd. (“Adlai Nortye” or “the Company”), a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, announced today that it has entered into a Global License Agreement (“the Agreement”) with Novartis Pharma AG, a global pharmaceutical company.

Eyemart Express is partnering with Visual Eyes Eyewear to mark the tenth anniversary of cancer research and awareness organization Stand Up To Cancer, also known as SU2C, with a fundraising campaign that includes a $25,000 minimum donation commitment.

ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.

A new non-profit initiative intended to radically curb the devastating rise of antibiotic resistance has launched from Seattle and is already gaining ground worldwide with more than 50 clinical and academic institutions across 20 countries expressing interest in joining the effort.

Evolva announces that, as part of entering the next phase of its evolution, the current Evolva CEO Simon Waddington steps down as CEO with immediate effect.

Takeda Pharmaceutical Company Limited announces that it has received unconditional clearance from the United States Federal Trade Commission (“FTC”) for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”).

This new grant will be dedicated to the development of the company’s platform for biomanufacturing long DNA constructs for cell and gene therapy applications.

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares

Sprint Bioscience has developed biomarkers for the company’s anti-cancer project, Vps34.